MA46058A - Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles - Google Patents

Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles

Info

Publication number
MA46058A
MA46058A MA046058A MA46058A MA46058A MA 46058 A MA46058 A MA 46058A MA 046058 A MA046058 A MA 046058A MA 46058 A MA46058 A MA 46058A MA 46058 A MA46058 A MA 46058A
Authority
MA
Morocco
Prior art keywords
chylomicrons
proteins
nucleic acids
cholesteryl ester
body cells
Prior art date
Application number
MA046058A
Other languages
English (en)
Inventor
Mary P Mccourt
Lawrence Mielnicki
Jerome J Schentag
Original Assignee
Mary P Mccourt
Lawrence Mielnicki
Jerome J Schentag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mary P Mccourt, Lawrence Mielnicki, Jerome J Schentag filed Critical Mary P Mccourt
Publication of MA46058A publication Critical patent/MA46058A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046058A 2016-08-23 2017-08-23 Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles MA46058A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662378599P 2016-08-23 2016-08-23

Publications (1)

Publication Number Publication Date
MA46058A true MA46058A (fr) 2019-07-03

Family

ID=61245234

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046058A MA46058A (fr) 2016-08-23 2017-08-23 Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles

Country Status (7)

Country Link
US (2) US20190175515A1 (fr)
EP (1) EP3503876A4 (fr)
JP (1) JP2019528294A (fr)
CN (1) CN110418636A (fr)
AU (1) AU2017315321A1 (fr)
MA (1) MA46058A (fr)
WO (1) WO2018039303A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
AU2014236559B2 (en) 2013-03-14 2020-03-12 Julie HUGHES Cholestosome vesicles for incorporation of molecules into chylomicrons
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CN115989511A (zh) * 2020-08-31 2023-04-18 武田药品工业株式会社 推理装置、推理方法、推理程序、模型生成方法、推理服务提供系统、推理服务提供方法以及推理服务提供程序
CN114099780A (zh) * 2020-08-31 2022-03-01 易成刚 同种异体或异种脂肪萃取液及其制备方法、应用
US20230288404A1 (en) * 2020-09-25 2023-09-14 Suzhou Ersheng Biopharmaceutical Co., Ltd. Detection method for tumor-specific t cells
CN115369091B (zh) * 2022-09-29 2023-07-28 成都赛诺联创生物科技有限公司 一种Caco-2细胞倒置模型及其制备方法
CN118207158B (zh) * 2023-06-21 2024-08-27 天津医科大学眼科医院 一种细胞内来源的纳米囊泡的制备方法及应用
WO2025226829A1 (fr) * 2024-04-23 2025-10-30 Ashvattha Therapeutics, Inc. Formulations de dendrimères et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US9119782B2 (en) * 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
CA2868362C (fr) * 2012-03-29 2018-07-31 Jerome Schentag Formulations de vaccination orale specifiques a un site gastro-intestinal actives sur l'ileon et l'appendice
AU2014236559B2 (en) * 2013-03-14 2020-03-12 Julie HUGHES Cholestosome vesicles for incorporation of molecules into chylomicrons
WO2016155809A1 (fr) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Formulations de particules lipidiques permettant la délivrance à une cellule cible d'arn et de composés hydrosolubles thérapeutiquement efficaces

Also Published As

Publication number Publication date
US20230240997A1 (en) 2023-08-03
EP3503876A4 (fr) 2020-06-10
JP2019528294A (ja) 2019-10-10
US20190175515A1 (en) 2019-06-13
AU2017315321A1 (en) 2019-04-11
EP3503876A1 (fr) 2019-07-03
WO2018039303A1 (fr) 2018-03-01
CN110418636A (zh) 2019-11-05

Similar Documents

Publication Publication Date Title
MA46058A (fr) Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MX2022015079A (es) Variantes de hsd17b13 y usos de las mismas.
IL269643A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP3528617A4 (fr) Peptides clivables et protéines insecticides et nématicides les comprenant
PL3310805T3 (pl) Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
EP3512948A4 (fr) Administration d'acides nucléiques, de protéines et de petites molécules dans des corps vésiculaires vitreux
SG10201710631RA (en) Artificial nucleic acid molecules for improved protein or peptide expression
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
MX360816B (es) Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
HUE042053T2 (hu) Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
EP4286400A3 (fr) Agents pharmaceutiques peptidiques améliorés
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
EP2959019A4 (fr) Méthodes de séquençage d'acides nucléiques présents dans des mélanges et compositions associées
EP3210997C0 (fr) Agents et procédés pour l'expression et la sécrétion de peptides et de protéines
EP3490538A4 (fr) Particules pour l'administration de protéines et de peptides
SG11201504877XA (en) Simultaneous detection of target protein and target nucleic acids in a single cell
EP3877526A4 (fr) Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques
EP4397374A3 (fr) Produits pharmaceutiques peptidiques améliorés contre l'insulinorésistance
EP3180463A4 (fr) Détection de protéines résiduelles de cellule hôte dans des préparations de protéines de recombinaison
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
EP3419962A4 (fr) Conjugués d'acides aminés et de peptides et procédé de conjugaison
EP3902556A4 (fr) Protéine cereblon modifiée in vivo
EP3615060A4 (fr) Peptides antigéniques de vhs et vaccins protéiques de vhs